Literature DB >> 17503071

Reduction in beta-myosin heavy chains in stunned myocardium as assessed by nondenaturing gel electrophoresis.

S C Garcia1, V J Pomblum, E Gams, H Rupp, J D Schipke.   

Abstract

Myosin plays a key role in the structure and function of cardiac muscle. Three myosin isoenzymes (V(1), V(2), and V(3)) with different ATPase activities have been identified in mammalian ventricles based on their heavy chain constituents. The relative amount of myosin isoenzymes changes under physiological and pathological conditions. Until now, myosin isoenzymes have frequently been determined using either tube gel (nondenaturing) polyacrylamide gel electrophoresis (PAGE), or gradient or uniform sodium dodecyl sulfate (denaturing) PAGE. Both methods have disadvantages, e.g., a long running time. We developed, therefore, a uniform, nondenaturing PAGE with slab minigel format for analyzing the myosin isoenzymes in normoxic and stunned rabbit hearts. In normoxic hearts of adult rabbits, V(3) predominated over V(1) (46 vs 41%). In turn, in the stunned hearts, V(1) predominated over V(3) (70 vs 30%), and the heterodimeric V(2) was not anymore detectable. This alteration appears to result from a selective loss of myosin heavy chain (MHC)-beta. In parallel, the biochemical markers troponin I and creatine kinase were increased in the stunned hearts. We suggest that alterations of myosin isoenzymes in stunned myocardium can be monitored with native PAGE. The present analysis of myosin isoenzyme appears thus as a new tool for evaluating defects in MHC dimer formation in postischemic hearts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503071     DOI: 10.1007/s00424-007-0268-5

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  34 in total

Review 1.  The role of troponin abnormalities as a cause for stunned myocardium.

Authors:  J E Van Eyk; A M Murphy
Journal:  Coron Artery Dis       Date:  2001-08       Impact factor: 1.439

2.  Alterations in myofibrillar function and protein profiles after complete global ischemia in rat hearts.

Authors:  M V Westfall; R J Solaro
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

3.  Functional significance of altered myosin adenosine triphosphatase activity in enlarged hearts.

Authors:  N R Alpert; L A Mulieri; R Z Litten
Journal:  Am J Cardiol       Date:  1979-10-22       Impact factor: 2.778

4.  Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences.

Authors:  E M McNally; R Kraft; M Bravo-Zehnder; D A Taylor; L A Leinwand
Journal:  J Mol Biol       Date:  1989-12-05       Impact factor: 5.469

5.  Myosin transitions in the bovine and human heart. A developmental and anatomical study of heavy and light chain subunits in the atrium and ventricle.

Authors:  P Cummins; S J Lambert
Journal:  Circ Res       Date:  1986-06       Impact factor: 17.367

6.  Utilization of oxygen by the contractile apparatus is disturbed during reperfusion of post-ischaemic myocardium.

Authors:  J D Schipke; U Sunderdiek; B Korbmacher; U Schwanke; G Arnold
Journal:  Eur Heart J       Date:  1995-11       Impact factor: 29.983

7.  Exercise and beta-adrenergic regulation of rat cardiac myosin isoforms.

Authors:  M E Wade; R A Herb; S K Powers; D Criswell
Journal:  J Sports Med Phys Fitness       Date:  1999-03       Impact factor: 1.637

8.  Electrophoretic separation and quantitation of cardiac myosin heavy chain isoforms in eight mammalian species.

Authors:  P J Reiser; W O Kline
Journal:  Am J Physiol       Date:  1998-03

9.  Ca2+ sensitivity change and troponin loss in cardiac natural actomyosin after coronary occlusion.

Authors:  T Toyo-Oka; J Ross
Journal:  Am J Physiol       Date:  1981-05

10.  Effects of physical training on the myocardium of streptozotocin-induced diabetic rats.

Authors:  N Takeda; I Nakamura; T Ohkubo; T Hatanaka; M Nagano
Journal:  Basic Res Cardiol       Date:  1988 Sep-Oct       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.